AI assistant
Medistim — Remuneration Information 2024
Apr 3, 2024
3662_dirs_2024-04-03_0bd7265b-391f-4320-b259-bcd7f92c7b11.html
Remuneration Information
Open in viewerOpens in your device viewer
CEO share program
CEO share program
Medistim ASA has transferred 8000 shares to CEO Kari Krogstad's 100% owned company K2 Consulting. This is according to the agreement entered between Medistim ASA and the CEO under the same terms as described in the press release from the 22end of January 2024. The shares have a lock up period of 3 years and this qualifies for a 25% discount. Average share price in the 14 days subscription period was NOK 193 per share. The shares were therefore purchased at 144,56 per share.
To finance the purchase, Medistim has given the CEO a loan and when the lock in period has ended, she is given a bonus equal to the loan amount. K2 Consulting AS has in total 23.500 shares after the purchase.
After these transactions Kari E. Krogstad controls in total 70.583 Medistim shares. Medistim ASA has 23.117 own shares after the transactions.